News
New Data Showing that Transgene and NEC’s Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses against Tumors Presented at AACR 2023
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation (NEC; TSE:
Glass Lewis Recommends Aurinia Shareholders Vote “FOR” ALL Company Director Nominees at 2023 Annual Meeting
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that Glass Lewis & Co. (“Glass Lewis”), a leading independent proxy advisor, has recommended that Aurinia
Poxel Announces Multiple TWYMEEG® (Imeglimin) Abstracts Accepted for Oral Presentation
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 4, 2023
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the first quarter of 2023, on Thursday, May 4, 2023
ISS Joins Glass Lewis in Recommending Aurinia Shareholders Vote “FOR” ALL Company Director Nominees at 2023 Annual General Meeting
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that leading independent proxy advisor Institutional Shareholder Services (“ISS”) has recommended that
Sangamo Therapeutics Announces First Quarter 2023 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company is scheduled to release its first quarter 2023 financial results after the market closes on
Silence Therapeutics Completes Enrollment in Phase 2 Study of Zerlasiran (SLN360) in Subjects with Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2023 Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, May 4, 2023, following the release of its first quarter
Sangamo Therapeutics Announces Strategic Update and Reports Preliminary First Quarter 2023 Financial Results
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced recent business highlights, including a strategic pipeline prioritization and restructuring, and reported
Toni Braxton and Aurinia Want People with Lupus Nephritis to Get Uncomfortable to Protect their Kidneys
Toni Braxton, the award-winning singer, songwriter, actress, producer, and entrepreneur is speaking out about living with lupus and the importance of prioritizing kidney health. In partnership with
Sangamo Therapeutics to Present Pre-clinical Data From Its Genomic Engineering Platform at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted 14 Sangamo abstracts for presentation at
IMV Initiates Restructuring Proceedings Under the CCAA to Complete the Review of its Strategic Alternatives
IMV Inc. (the “Company” or “IMV”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical Company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Investor Conference
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through
EQS-News: Abivax: Publication of an expert article in JCC on obefazimod as promising therapeutic management option for UC patients
Abivax postpones the publication of its 2023 Universal Registration Document
EQS-News: MPH Health Care AG: Preliminary IFRS result 2022
EQS-News: Formycon publishes results for financial year 2022
Kuros reports 168% increase in direct MagnetOs sales in the first quarter of 2023
EQS-News: Formycon announces successful results of Phase I clinical trial for ustekinumab biosimilar candidate FYB202 and concludes clinical development
Evolva publishes timeline of the Reverse Stock Split
EQS-News: Abivax reports 2022 financial results and operations update
EQS-News: Abivax appoints Michael Ferguson as Chief Commerical Officer
Evolva shareholders approve all motions proposed by the Board at today’s Annual General Meeting
EQS-News: Abivax reports two-year efficacy and safety data of obefazimod phase 2b maintenance trial in ulcerative colitis
EQS-News: Abivax appoints Marc de Garidel as Chief Executive Officer and Interim Board Chair